Analysts Issue Forecasts for Replimune Group Q3 Earnings

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Replimune Group in a research report issued on Friday, May 23rd. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($0.66) for the quarter. HC Wainwright has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for Replimune Group's current full-year earnings is ($2.97) per share. HC Wainwright also issued estimates for Replimune Group's Q4 2026 earnings at ($0.56) EPS and FY2026 earnings at ($2.89) EPS.

Separately, JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Replimune Group has an average rating of "Buy" and an average target price of $19.43.

Replimune Group Trading Down 4.7%

Shares of Replimune Group stock traded down $0.45 during mid-day trading on Monday, hitting $8.93. The stock had a trading volume of 325,121 shares, compared to its average volume of 924,016. The firm has a 50-day moving average of $8.42 and a two-hundred day moving average of $11.11. The firm has a market cap of $688.00 million, a P/E ratio of -2.91 and a beta of 0.68. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the previous year, the business earned ($0.25) earnings per share.

Insiders Place Their Bets

In related news, insider Konstantinos Xynos sold 7,952 shares of Replimune Group stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the transaction, the insider now owns 146,933 shares in the company, valued at $1,184,279.98. The trade was a 5.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Christopher Sarchi sold 3,749 shares of the business's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $30,179.45. Following the transaction, the insider now owns 128,296 shares of the company's stock, valued at approximately $1,032,782.80. The trade was a 2.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 74,907 shares of company stock worth $603,655 in the last ninety days. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

A number of institutional investors have recently bought and sold shares of REPL. Sterling Capital Management LLC increased its holdings in shares of Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after acquiring an additional 1,655 shares during the last quarter. US Bancorp DE increased its stake in Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after purchasing an additional 3,921 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after purchasing an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd lifted its position in shares of Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after buying an additional 8,183 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Replimune Group by 897.2% during the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock worth $902,000 after buying an additional 7,913 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.